HomeCompareCHGCY vs JEPQ

CHGCY vs JEPQ: Dividend Comparison 2026

CHGCY yields 2.99% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCY wins by $405.78M in total portfolio value· pulled ahead in Year 3
10 years
CHGCY
CHGCY
● Live price
2.99%
Share price
$27.52
Annual div
$0.82
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$405.82M
Annual income
$381,294,826.82
Full CHGCY calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — CHGCY vs JEPQ

📍 CHGCY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCYJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCY + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHGCY pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCY
Annual income on $10K today (after 15% tax)
$253.82/yr
After 10yr DRIP, annual income (after tax)
$324,100,602.80/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, CHGCY beats the other by $324,098,773.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCY + JEPQ for your $10,000?

CHGCY: 50%JEPQ: 50%
100% JEPQ50/50100% CHGCY
Portfolio after 10yr
$202.93M
Annual income
$190,648,489.70/yr
Blended yield
93.95%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCY buys
9
JEPQ buys
0
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002025-04-09
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002024-06-21
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002024-04-04
Josh Gottheimer🏢 House$CHGCY▲ Buy$1,001 - $15,0002023-08-18
Daniel Goldman🏢 House$CHGCY▼ Sell$1,001 - $15,0002023-07-10
Daniel Goldman🏢 House$CHGCY▼ Sell$15,001 - $50,0002023-03-31
Daniel Goldman🏢 House$CHGCY▲ Buy$1,001 - $15,0002023-02-27
Peter Meijer🏢 House$CHGCY▼ Sell$15,001 - $50,0002021-02-17
Greg Gianforte🏢 House$CHGCY▼ Sell$50,001 - $100,0002020-04-14
Josh Gottheimer🏢 House$CHGCY▼ Sell$1,001 - $15,0002020-04-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCYJEPQ
Forward yield2.99%11.10%
Annual dividend / share$0.82$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0%
Portfolio after 10y$405.82M$44.8K
Annual income after 10y$381,294,826.82$2,152.59
Total dividends collected$404.01M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CHGCY vs JEPQ ($10,000, DRIP)

YearCHGCY PortfolioCHGCY Income/yrJEPQ PortfolioJEPQ Income/yrGap
1$11,297$597.22$11,930$1,110.39$633.00JEPQ
2$13,349$1,261.10$14,133$1,224.34$784.00JEPQ
3← crossover$17,069$2,785.33$16,632$1,340.46+$437.00CHGCY
4$24,921$6,656.96$19,454$1,457.97+$5.5KCHGCY
5$44,832$18,166.72$22,626$1,576.08+$22.2KCHGCY
6$109,057$61,087.10$26,175$1,694.09+$82.9KCHGCY
7$394,447$277,755.94$30,133$1,811.32+$364.3KCHGCY
8$2,299,836$1,877,777.60$34,531$1,927.17+$2.27MCHGCY
9$22,925,198$20,464,373.86$39,403$2,041.08+$22.89MCHGCY
10$405,824,789$381,294,826.82$44,787$2,152.59+$405.78MCHGCY

CHGCY vs JEPQ: Complete Analysis 2026

CHGCYStock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCY Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this CHGCY vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCY vs SCHDCHGCY vs JEPICHGCY vs OCHGCY vs KOCHGCY vs MAINCHGCY vs XYLDCHGCY vs QYLDCHGCY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.